Swedish Orphan Biovitrum (Sobi) has confirmed that the company is holding discussions with a private equity firm regarding a possible sale of its Partner Products business area.

In the January-September period last year, the Partner Products unit reported sales of $70m, while the company’s total sales stood at $444m, Reuters reported.

Sobi CEO and president Geoffrey McDonough said: “We have noted specific information in the market regarding a possible sale of Sobi Partner Products.

“We confirm that we are in discussions which may or may not lead to an agreement.”

The sale excludes drugs Kineret and Orfadin.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"We have noted specific information in the market regarding a possible sale of Sobi Partner Products."

Sobi said that the European Commission (EC) has approved a reduced dosing frequency for the drug Orfadin (nitisinone) from twice-daily to once-daily in people with hereditary tyrosinemia type 1 (HT-1) with a body weight of more than 20kg.

Sobi research and development senior vice-president, chief medical officer and head Dr Milan Zdravkovic said: “Sobi has a long-term commitment to improve the lives of people affected by hereditary tyrosinemia type 1, and the above modified dosing regimen is a further step in this journey.”

EC’s approval is based on the results of a clinical study carried out in 18 people with HT-1, comparing a four week once-daily and four week twice-daily dosing regimen.

As part of the study, comparable blood-levels of nitisinone, as well as safety and efficacy for both regimens were highlighted.

Image: Sobi to sell Partner Products business area. Photo: courtesy of Swedish Orphan Biovitrum AB.